TWD 361.5
(-0.14%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 3.57 Billion TWD | 7.71% |
2022 | 3.31 Billion TWD | 11.85% |
2021 | 2.96 Billion TWD | 47.88% |
2020 | 2 Billion TWD | 34.26% |
2019 | 1.49 Billion TWD | -7.0% |
2018 | 1.6 Billion TWD | 52.95% |
2017 | 1.04 Billion TWD | 24.93% |
2016 | 840.16 Million TWD | 25.49% |
2015 | 669.5 Million TWD | 51.3% |
2014 | 442.48 Million TWD | 41.4% |
2013 | 312.92 Million TWD | 185.5% |
2012 | 109.6 Million TWD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q1 | 995.69 Million TWD | -13.66% |
2024 Q2 | 924.86 Million TWD | -7.11% |
2024 Q3 | 869.65 Million TWD | -5.97% |
2023 Q1 | 766.1 Million TWD | -17.14% |
2023 Q3 | 899.4 Million TWD | 9.02% |
2023 Q2 | 825 Million TWD | 7.69% |
2023 Q4 | 1.15 Billion TWD | 28.22% |
2023 FY | 3.57 Billion TWD | 7.71% |
2022 Q4 | 924.61 Million TWD | 10.27% |
2022 Q2 | 758.87 Million TWD | -4.35% |
2022 FY | 3.31 Billion TWD | 11.85% |
2022 Q1 | 793.41 Million TWD | -6.14% |
2022 Q3 | 838.53 Million TWD | 10.5% |
2021 Q1 | 597.43 Million TWD | -19.7% |
2021 FY | 2.96 Billion TWD | 47.88% |
2021 Q4 | 845.35 Million TWD | 5.49% |
2021 Q3 | 801.39 Million TWD | 11.29% |
2021 Q2 | 720.12 Million TWD | 20.54% |
2020 Q2 | 411.24 Million TWD | 26.33% |
2020 FY | 2 Billion TWD | 34.26% |
2020 Q3 | 523.75 Million TWD | 27.36% |
2020 Q1 | 325.54 Million TWD | -29.28% |
2020 Q4 | 743.98 Million TWD | 42.05% |
2019 Q3 | 377.73 Million TWD | 25.47% |
2019 Q2 | 301.05 Million TWD | -14.93% |
2019 Q1 | 353.89 Million TWD | -20.72% |
2019 FY | 1.49 Billion TWD | -7.0% |
2019 Q4 | 460.33 Million TWD | 21.87% |
2018 Q4 | 446.38 Million TWD | -2.68% |
2018 FY | 1.6 Billion TWD | 52.95% |
2018 Q3 | 458.68 Million TWD | 23.87% |
2018 Q2 | 370.28 Million TWD | 5.75% |
2018 Q1 | 350.14 Million TWD | 25.64% |
2017 Q3 | 278.68 Million TWD | 13.23% |
2017 Q1 | 246.11 Million TWD | 10.04% |
2017 FY | 1.04 Billion TWD | 24.93% |
2017 Q4 | 278.68 Million TWD | 0.0% |
2017 Q2 | 246.11 Million TWD | 0.0% |
2016 Q1 | 196.42 Million TWD | 10.06% |
2016 Q2 | 196.42 Million TWD | 0.0% |
2016 Q3 | 223.65 Million TWD | 13.86% |
2016 FY | 840.16 Million TWD | 25.49% |
2016 Q4 | 223.65 Million TWD | 0.0% |
2015 Q4 | 178.46 Million TWD | 0.0% |
2015 Q2 | 156.28 Million TWD | 0.0% |
2015 Q3 | 178.46 Million TWD | 14.19% |
2015 Q1 | 156.28 Million TWD | 18.58% |
2015 FY | 669.5 Million TWD | 51.3% |
2014 Q2 | 89.45 Million TWD | 0.0% |
2014 Q3 | 131.79 Million TWD | 47.34% |
2014 FY | 442.48 Million TWD | 41.4% |
2014 Q4 | 131.79 Million TWD | 0.0% |
2014 Q1 | 89.45 Million TWD | 17.32% |
2013 Q2 | 80.21 Million TWD | 0.0% |
2013 Q4 | 76.24 Million TWD | 0.0% |
2013 Q1 | 80.21 Million TWD | 0.0% |
2013 FY | 312.92 Million TWD | 185.5% |
2013 Q3 | 76.24 Million TWD | -4.95% |
2012 FY | 109.6 Million TWD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Nang Kuang Pharmaceutical Co., Ltd. | 755.56 Million TWD | -372.647% |
Maxigen Biotech Inc. | 424.09 Million TWD | -742.064% |
SciVision Biotech Inc. | 512.49 Million TWD | -596.817% |
Bionime Corporation | 715.65 Million TWD | -399.007% |
Visco Vision Inc. | 857.15 Million TWD | -316.627% |